Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
University of California, Los Angeles |
---|---|
Information provided by: | University of California, Los Angeles |
ClinicalTrials.gov Identifier: | NCT00719030 |
The purpose of this study is to compare the effects of pomegranate pills and a placebo (sugar pill) on prostatic oxidative. The placebo is a pill that looks like the POM-X pill but does not have an active ingredient. Participants and their study doctor will know which study group they are in. If participants prostate cancer progresses while they are in the study, they will be withdrawn from the study. If it turns out that they are on the placebo, they will be eligible to enter into another study where they will receive the pomegranate pill.
Condition | Intervention |
---|---|
Prostate Cancer |
Dietary Supplement: Pomegranate pill Dietary Supplement: Pomegranate pill placebo |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Placebo-Controlled, Pre-Surgical Study of the Effects of Pomegranate Pills in Men With Prostate Cancer Prior to Radical Prostatectomy |
Estimated Enrollment: | 35 |
Study Start Date: | June 2008 |
Estimated Primary Completion Date: | July 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Pomegranate pill
|
Dietary Supplement: Pomegranate pill
Pomegranate extract pill
|
2: Placebo Comparator |
Dietary Supplement: Pomegranate pill placebo
Pomegranate pill placebo
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Allan Pantuck, M.D. | 310-206-2436 | apantuck@mednet.ucla.edu |
Contact: Jean DeKernion, M.D. | 310-206-6453 |
United States, California | |
UCLA | Recruiting |
Los Angeles, California, United States, 90095 | |
Contact: Allan Pantuck 310-206-2436 apantuck@mednet.ucla.edu | |
Principal Investigator: Allan Pantuck, M.D. |
Responsible Party: | UCLA ( Allan Pantuck, M.D. ) |
Study ID Numbers: | GUP-0515-02 |
Study First Received: | July 15, 2008 |
Last Updated: | July 17, 2008 |
ClinicalTrials.gov Identifier: | NCT00719030 |
Health Authority: | United States: Institutional Review Board |
Prostatic Diseases Genital Neoplasms, Male Urogenital Neoplasms Genital Diseases, Male Prostatic Neoplasms |
Neoplasms Neoplasms by Site |